|Articles|August 15, 2017

Broad Technology Toolkit to Accelerate Drug Development

Author(s)Catalent

Catalent has the broadest range of technologies and solutions to overcome developmental and bioavailability challenges, and to enhance product performance.

Catalent is the leading global provider of advanced drug delivery technologies and development solutions for drugs, biologics, and consumer health products. The company has over 80 years’ experience serving the pharmaceutical industry, and proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable product supply.

 

Catalent’s solutions include analytical, pre-formulation and formulation technologies and expertise, and with the recent addition of spray dry dispersion specialist Pharmatek, it now offers further early development capabilities and the most comprehensive toolkit of bioavailability enhancing technologies. Catalent produces over 70 billion oral, sterile, biologic, and inhaled doses each year, for clients across five continents.

 

Built on its experience in early phase development, which has seen the company support more than 500 INDs, Catalent has extended the scope of its multi-award winning OptiForm® Solution Suite. This integrates multiple tools and services to deliver customised development programmes that provide innovators with a data-driven, key milestone approach and a thorough analysis of important drug molecule characteristics at each stage, including consideration of downstream processing and optimal dose design for the intended patient group, to improve the chances of success in both the clinic and beyond.

Catalent. More products. Better treatments. Reliably supplied.™

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.